• Je něco špatně v tomto záznamu ?

Prenatal exposure to opioid maintenance treatment and neonatal outcomes: Nationwide registry studies from the Czech Republic and Norway

M. Handal, B. Nechanská, S. Skurtveit, IO. Lund, R. Gabrhelík, A. Engeland, V. Mravčík,

. 2019 ; 7 (5) : e00501. [pub] 20190814

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, pozorovací studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023744

Grantová podpora
NV16-28157A MZ0 CEP - Centrální evidence projektů

There is lack of knowledge about the safety of treatment with methadone and buprenorphine as part of opioid maintenance treatment (OMT) during pregnancy. The purpose of this study was to examine neonatal outcomes concerning the use of OMT during pregnancy. We used nationwide registry linkages from the Czech Republic (2000-2014) and Norway (2004-2013). We compared prenatally OMT-exposed newborns with (a) newborns of women hospitalized with opioid use disorder during pregnancy in the Czech sample and (b) newborns with neonatal abstinence syndrome (NAS) in Norway. We performed multivariate linear and binary logistic regression exploring the associations between OMT and neonatal outcomes (growth parameters, gestational age, fetal death, small for gestational age, Apgar score, and NAS). Regression coefficients (b) and odds ratios (ORs) were estimated. The cohorts consisted of 333 Czech, and 235 Norwegian OMT-exposed newborns, and 106 and 294 newborns in the comparison groups, respectively. In both countries, the neonatal growth parameters were similar in the OMT and the comparison groups. In Norway, OMT exposure prolonged gestational age (adjusted b = 0.96 weeks, 95% confidence interval [CI] =0.39-1.53) while the odds of preterm birth and Apgar score at 5 minutes were lower than in the comparison group (adjusted OR = 0.35, 0.16-0.75 and aOR = 0.21, 0.06-0.78, respectively). Newborns of women in OMT had similar growth parameters as newborns of women with opioid use disorders who were not in OMT during pregnancy. Overall, our findings do not suggest that OMT results in worse neonatal outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023744
003      
CZ-PrNML
005      
20201214131030.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/prp2.501 $2 doi
035    __
$a (PubMed)31428431
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Handal, Marte $u Department of Mental Disorders Norwegian Institute of Public Health Oslo Norway.
245    10
$a Prenatal exposure to opioid maintenance treatment and neonatal outcomes: Nationwide registry studies from the Czech Republic and Norway / $c M. Handal, B. Nechanská, S. Skurtveit, IO. Lund, R. Gabrhelík, A. Engeland, V. Mravčík,
520    9_
$a There is lack of knowledge about the safety of treatment with methadone and buprenorphine as part of opioid maintenance treatment (OMT) during pregnancy. The purpose of this study was to examine neonatal outcomes concerning the use of OMT during pregnancy. We used nationwide registry linkages from the Czech Republic (2000-2014) and Norway (2004-2013). We compared prenatally OMT-exposed newborns with (a) newborns of women hospitalized with opioid use disorder during pregnancy in the Czech sample and (b) newborns with neonatal abstinence syndrome (NAS) in Norway. We performed multivariate linear and binary logistic regression exploring the associations between OMT and neonatal outcomes (growth parameters, gestational age, fetal death, small for gestational age, Apgar score, and NAS). Regression coefficients (b) and odds ratios (ORs) were estimated. The cohorts consisted of 333 Czech, and 235 Norwegian OMT-exposed newborns, and 106 and 294 newborns in the comparison groups, respectively. In both countries, the neonatal growth parameters were similar in the OMT and the comparison groups. In Norway, OMT exposure prolonged gestational age (adjusted b = 0.96 weeks, 95% confidence interval [CI] =0.39-1.53) while the odds of preterm birth and Apgar score at 5 minutes were lower than in the comparison group (adjusted OR = 0.35, 0.16-0.75 and aOR = 0.21, 0.06-0.78, respectively). Newborns of women in OMT had similar growth parameters as newborns of women with opioid use disorders who were not in OMT during pregnancy. Overall, our findings do not suggest that OMT results in worse neonatal outcomes.
650    _2
$a dospělí $7 D000328
650    _2
$a buprenorfin $x terapeutické užití $7 D002047
650    _2
$a vývoj dítěte $7 D002657
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a novorozenec $7 D007231
650    _2
$a logistické modely $7 D016015
650    _2
$a methadon $x terapeutické užití $7 D008691
650    _2
$a novorozenecký abstinenční syndrom $x epidemiologie $7 D009357
650    _2
$a opiátová substituční terapie $7 D058850
650    _2
$a poruchy spojené s užíváním opiátů $x farmakoterapie $7 D009293
650    _2
$a těhotenství $7 D011247
650    _2
$a komplikace těhotenství $x farmakoterapie $7 D011248
650    _2
$a zpožděný efekt prenatální expozice $x epidemiologie $7 D011297
650    _2
$a registrace $7 D012042
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Česká republika $x epidemiologie $7 D018153
651    _2
$a Norsko $x epidemiologie $7 D009664
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nechanská, Blanka $u Department of Addictology, First Faculty of Medicine Charles University Prague Czech Republic. Institute of Health Information and Statistics of the Czech Republic Prague Czech Republic.
700    1_
$a Skurtveit, Svetlana $u Department of Mental Disorders Norwegian Institute of Public Health Oslo Norway. Norwegian Centre for Addiction Research at the University of Oslo Oslo Norway.
700    1_
$a Lund, Ingunn Olea $u Department of Mental Disorders Norwegian Institute of Public Health Oslo Norway.
700    1_
$a Gabrhelík, Roman $u Department of Addictology, First Faculty of Medicine Charles University Prague Czech Republic.
700    1_
$a Engeland, Anders $u Department of Chronic Diseases and Ageing Norwegian Institute of Public Health Oslo Norway. Department of Global Public Health and Primary Care University of Bergen Bergen Norway.
700    1_
$a Mravčík, Viktor $u Department of Addictology, First Faculty of Medicine Charles University Prague Czech Republic. National Monitoring Centre for Drugs and Addiction Office of the Government of the Czech Republic Prague Czech Republic.
773    0_
$w MED00190080 $t Pharmacology research & perspectives $x 2052-1707 $g Roč. 7, č. 5 (2019), s. e00501
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31428431 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214131028 $b ABA008
999    __
$a ok $b bmc $g 1596063 $s 1114420
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 7 $c 5 $d e00501 $e 20190814 $i 2052-1707 $m Pharmacology research & perspectives $n Pharmacol Res Perspect $x MED00190080
GRA    __
$a NV16-28157A $p MZ0
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace